BioMarin is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once ...

A Senate committee has rejected President Donald Trump’s efforts to gouge funding for the National Institutes of Health (NIH) ...

Skin-focused Sirona Biochem is liquidating its R&D subsidiary after a pair of financing deals and a licensing agreement with ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

OrbiMed’s website lists 134 biopharma companies across the firm’s portfolio. Recent investments the firm has participated in ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The FDA formally kicked off its quinquennial process to reauthorize the federal user fee legislation that helps fund its ...

Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...

The brain-computer interface developer Synchron has shown that its minimally invasive device can help connect a patient with ...